Analysis on Clinical Effect and Safety of Chemotherapy Combined with Aromatase Inhibitor in the Treatment of Patients with Postmenopausal Positive Hormone Receptor Breast Cancer
Objective To analyze the clinical effect and safety of chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer.Methods 90 patients with postmenopausal positive hormone receptor breast cancer admitted to our hospital from February 2020 to June 2022 were selected and randomly divided into reference group(45 cases)and combined group(45 cases).The reference group was treated with TE(docetaxel+epirubicin)chemotherapy,and the combined group was treated with anastrozole on the basis of the reference group.The objective response rate(ORR)and the incidence of adverse reactions were compared between the two groups.Results The ORR of the combined group was 55.56%,significantly higher than 33.33%of the reference group(P<0.05).During the treatment,the incidence of adverse reactions in the combined group was 31.11%,which had no statistical difference with 37.78%in the reference group(P>0.05).Conclusions Chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer,can significantly improve the clinical efficacy,but does not significantly increase the incidence of adverse reactions with higher safety.
Breast cancerPositive hormone receptorAromatase inhibitorChemotherapyClinical efficacySafety
国家科技期刊平台
NSTL
万方数据
